Biotin is widely used in immunoassay type laboratory methods over a wide range of instruments at numerous clinical laboratories throughout the world (including Spectrum Health).
With the expansion of biotin – also known as vitamin B7 – supplementation and treatments (“over the counter” and prescription, respectively); an associated interference with many clinical laboratory tests has been identified, confirmed and documented. Unfortunately, magnitude and type (falsely increased/decreased) of interference varies with dose and assay; however, it has been confirmed that as dose increases so does the magnitude of the response. In late November 2017, the Food and Drug Administration (FDA) published a safety alert warning that biotin can interfere with certain lab tests and cause incorrect test results.
Effective Monday, July 2, 2018, the outpatient laboratory (“draw site”) in Butterworth Hospital will have new hours of operation.
High sensitivity flow cytometry testing for paroxysmal nocturnal hemoglobinuria (PNH) is a test done on patient’s peripheral blood to screen for the presence or absence of PNH clones and/or to follow PNH clonal populations. The lower limit of detection of a PNH clone for the Spectrum Health laboratory has been validated as 0.01% (1:10,000) for red cells, 0.01% (1:10,000) for granulocytes and 0.1% for monocytes (1:1000).
The results from PNH flow cytometry testing can guide the clinical team in classifying a patient’s disease appropriately, analyzing the risk of disease progression, and choosing appropriate testing to monitor response to treatment. Therefore, the PNH flow cytometry test result will now include a pathologist’s interpretation based on the new recommendations given in Updated ICCS/ESCCA Consensus Guidelines for the Clinical Utility of Testing for GPI-Anchor Deficient Clones in Paroxysmal Nocturnal Hemoglobinuria (PNH) and other Bone Marrow Disorders (Accepted article by Dezern and Borowitz, doi: 10.1002/cyto.b.21608).
Spectrum Health Laboratory Services are now available at Health Pointe
15100 Whittaker Way,
Grand Haven, MI 49417
Monday through Friday, 6:30 a.m. to 5 p.m.
Saturday, 7 a.m. to 12 p.m.
Effective immediately, Anti-Thyroglobulin (Anti-TgAb) requests if received in conjunction with Thyroglobulin Tumor Marker (Tg-TM) requests, will be canceled. Tg-TM tests are sent to Mayo Medical Laboratory; where both Tg-TM and Anti-TgAb are performed and resulted as part of the Tg-TM order. This is a laboratory best practice as anti-thyroglobulin autoantibodies (Anti-TgAb), which occur in 15% to 30% of thyroid cancer patients, could lead to misleading Tg results (falsely positive or falsely negative).
Questions may be directed to Dr. David Alter, using the “Contact Us” link above.
Spectrum Health Regional Laboratory now has ONE centralized fax number to which you can send your lab orders! This means no more searching for the fax number for a particular draw site for your patient. We will enter the faxed orders into our system, making them available to ALL of our draw sites; so your patient will have access to their order at their favorite draw site and the added convenience of going to any draw site that they choose!
*The new fax line number is: 616-774-7696
*If you are faxing an order for a patient that plans to go to a draw site immediately, please write “Patient En Route” on the order, so that it may be prioritized.
* Please note: Specimen add-on orders (additional tests for specimens in-lab) are still faxed to 616-267-2751, as stated on the add-on form.
Spectrum Health Laboratory Services will be available at the Spectrum Health Caledonia on February 5, 2018.
9090 South Rodgers Court
Caledonia, MI 49316
Hours: Monday through Friday 7 a.m. to 5 p.m.
Any laboratory testing order can be faxed to (616) 774-7696 and that order will be accessible from any Spectrum Laboratory Draw Site in the Grand Rapids, Big Rapids, Gerber (Fremont) and Zeeland area.
Influenza is currently widespread throughout the nation at epidemic proportions. During influenza epidemics, clinical assessment predicts the presence of influenza infection virtually as well as laboratory testing. Therefore, it is no longer necessary to perform viral testing on ambulatory patients who present with illness consistent with influenza before beginning antiviral treatment. Antiviral treatment for Influenza should be started as soon as possible to have a beneficial effect.
Shortages of supplies and medications frequently occur during Influenza epidemics. However, diagnosis of specific viral respiratory infection remains important for hospitalized patients.
Please follow the current recommendations:
- Limit availability of viral transport media at ambulatory sites.
- Emergency departments are to limit viral respiratory testing to patients expected to be admitted.
- Do not perform testing for test of cure.
Thank you for your support during this time. Please direct any questions to Laboratory Services via the “contact us” link above.